{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T04:14:52Z","timestamp":1768709692491,"version":"3.49.0"},"reference-count":26,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["jpharmsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1016\/j.xphs.2018.10.035","type":"journal-article","created":{"date-parts":[[2018,10,29]],"date-time":"2018-10-29T12:54:50Z","timestamp":1540817690000},"page":"1227-1235","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Effect of Overencapsulation on the Disintegration and Dissolution of Licensed Formulations for Blinding in Randomized Controlled Trials"],"prefix":"10.1016","volume":"108","author":[{"given":"Sam","family":"Maher","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen J.","family":"Walsh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josephine","family":"Takyi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abel","family":"Wakai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David J.","family":"Brayden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John C.","family":"Hayden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.xphs.2018.10.035_bib1","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1056\/NEJMms1604593","article-title":"Assessing the gold standard-lessons from the history of RCTs","volume":"374","author":"Bothwell","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.xphs.2018.10.035_bib2","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1093\/ije\/dyr162","article-title":"Commentary: the evolution of methods to assess the effects of treatments, illustrated by the development of treatments for diphtheria, 1825-1918","volume":"42","author":"Opinel","year":"2013","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.xphs.2018.10.035_bib3","series-title":"Blinding as a Solution to Bias: Strengthening Biomedical Science, Forensic Science, and Law","first-page":"45","article-title":"From trials to trials: blinding, medicine, and honest adjudication","author":"Podolsky","year":"2016"},{"key":"10.1016\/j.xphs.2018.10.035_bib4","series-title":"Cochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series","first-page":"187","article-title":"Assessing risk of bias in included studies","author":"Higgins","year":"2008"},{"key":"10.1016\/j.xphs.2018.10.035_bib5","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1136\/archdischild-2013-304037","article-title":"Blinding in pharmacological trials: the devil is in the details","volume":"98","author":"Wan","year":"2013","journal-title":"Arch Dis Child"},{"issue":"9810","key":"10.1016\/j.xphs.2018.10.035_bib6","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/S0140-6736(12)60024-5","article-title":"The unobtainable placebo: control of independent clinical research by industry?","volume":"379","author":"Christensen","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.xphs.2018.10.035_bib7","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1056\/NEJMe1010348","article-title":"Products at risk","volume":"363","author":"Curfman","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.xphs.2018.10.035_bib8","series-title":"Guideline on the requirements to the chemical and pharmaceutical quality documentation concerning investigational medicinal products in clinical trials (CHMP\/QWP\/185401\/2004)","year":"2017"},{"key":"10.1016\/j.xphs.2018.10.035_bib9","series-title":"Evaluating regulatory risk for comparator drug products","year":"2011"},{"issue":"2","key":"10.1016\/j.xphs.2018.10.035_bib10","first-page":"92","article-title":"Analytical development strategies for comparator products","volume":"6","author":"Huynh-Ba","year":"2003","journal-title":"Am Pharm Rev"},{"key":"10.1016\/j.xphs.2018.10.035_bib11","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1177\/0091270009356298","article-title":"Pharmacokinetics and pharmacodynamics of three moxifloxacin dosage forms: implications for blinding in active-controlled cardiac repolarization studies","volume":"50","author":"Mason","year":"2010","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.xphs.2018.10.035_bib12","doi-asserted-by":"crossref","first-page":"51","DOI":"10.5414\/CPP43051","article-title":"Esomeprazole MUPS 40 mg tablets and esomeprazole MUPS 40 mg tablets encapsulated in hard gelatine are bioequivalent","volume":"43","author":"Talpes","year":"2005","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.xphs.2018.10.035_bib13","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/S0149-2918(01)80006-0","article-title":"Effect of encapsulation on absorption of sumatriptan tablets: data from healthy volunteers and patients during a migraine","volume":"23","author":"Fuseau","year":"2001","journal-title":"Clin Ther"},{"key":"10.1016\/j.xphs.2018.10.035_bib14","doi-asserted-by":"crossref","first-page":"33","DOI":"10.7861\/clinmedicine.5-1-33","article-title":"Over-regulation of clinical research: a threat to public health","volume":"5","author":"Warlow","year":"2005","journal-title":"Clin Med"},{"key":"10.1016\/j.xphs.2018.10.035_bib15","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1208\/s12248-016-9877-2","article-title":"BCS biowaivers: similarities and\u00a0differences among EMA, FDA, and WHO requirements","volume":"18","author":"Davit","year":"2016","journal-title":"AAPS J"},{"key":"10.1016\/j.xphs.2018.10.035_bib16","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1023\/A:1016025817183","article-title":"Investigations into the relationship between drug properties, filling, and the release of drugs from hard gelatin capsules using multivariate statistical analysis","volume":"13","author":"Hogan","year":"1996","journal-title":"Pharm Res"},{"issue":"4","key":"10.1016\/j.xphs.2018.10.035_bib17","first-page":"104","article-title":"The effect of overencapsulation on disintegration and dissolution","volume":"34","author":"Esseku","year":"2010","journal-title":"Pharm Technol"},{"key":"10.1016\/j.xphs.2018.10.035_bib18","first-page":"508","article-title":"Uniformity of weight test: a non-destructive test compared to the European pharmacopoeia test","volume":"63","author":"Hoppe-Tichy","year":"2008","journal-title":"Pharmazie"},{"key":"10.1016\/j.xphs.2018.10.035_bib19","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.1002\/jps.24303","article-title":"Oral solid dosage form disintegration testing - the forgotten test","volume":"104","author":"Al-Gousous","year":"2015","journal-title":"J\u00a0Pharm Sci"},{"key":"10.1016\/j.xphs.2018.10.035_bib20","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0928-0987(01)00095-1","article-title":"Modeling and comparison of dissolution profiles","volume":"13","author":"Costa","year":"2001","journal-title":"Eur J Pharm Sci"},{"key":"10.1016\/j.xphs.2018.10.035_bib21","series-title":"Formulation considerations for overencapsulation of clinical trial materials in DBcaps capsules. Capsugel Library, BAS 251 E","author":"Lai","year":"2003"},{"key":"10.1016\/j.xphs.2018.10.035_bib22","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1081\/PDT-120024691","article-title":"Effect of fill weight, capsule shell, and sinker design on the dissolution behavior of capsule formulations of a weak acid drug candidate BMS-309403","volume":"8","author":"Wu","year":"2003","journal-title":"Pharm Dev Technol"},{"issue":"3","key":"10.1016\/j.xphs.2018.10.035_bib23","first-page":"48","article-title":"Effect of variations in backfill on dissolution for an overencaspulated comparator product","volume":"19","author":"Faust","year":"1999","journal-title":"Pharm Eng"},{"key":"10.1016\/j.xphs.2018.10.035_bib24","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jpba.2011.04.026","article-title":"Development of a two-step tier-2 dissolution method for blinded overencapsulated erlotinib tablets using UV fiber optic detection","volume":"56","author":"Lu","year":"2011","journal-title":"J\u00a0Pharm Biomed Anal"},{"key":"10.1016\/j.xphs.2018.10.035_bib25","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/0378-5173(93)90338-G","article-title":"Evaluation of the properties of microcrystalline and microfine cellulose powders","volume":"91","author":"Podczeck","year":"1993","journal-title":"Int J Pharm"},{"issue":"6","key":"10.1016\/j.xphs.2018.10.035_bib26","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/S0731-7085(99)00231-9","article-title":"Second-derivative UV spectrometric determination of simvastatin in its tablet dosage form","volume":"21","author":"Wang","year":"2000","journal-title":"J\u00a0Pharm Biomed Anal"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354918306671?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354918306671?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,2,13]],"date-time":"2019-02-13T06:32:48Z","timestamp":1550039568000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354918306671"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["S0022354918306671"],"URL":"https:\/\/doi.org\/10.1016\/j.xphs.2018.10.035","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of Overencapsulation on the Disintegration and Dissolution of Licensed Formulations for Blinding in Randomized Controlled Trials","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xphs.2018.10.035","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 American Pharmacists Association\u00ae. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}